AI Image
What's next for cancer vaccines after successful melanoma study
STAT • • business
Key Points:
- A pivotal trial presented at the European Society for Medical Oncology meeting showed that a customized mRNA vaccine, intismeran, combined with Merck’s Keytruda, reduced the risk of melanoma recurrence or death by 42% compared to Keytruda alone.
- This trial marks a significant breakthrough in cancer treatment, overcoming a century-long struggle to develop effective cancer vaccines.
- Experts suggest that this mRNA vaccine approach could potentially be applied to other types of tumors beyond melanoma.
- The positive results have sparked discussions among specialists about how to integrate this novel treatment into clinical practice and its broader deployment.
